Over the past decade, cardiac transthyretin amyloidosis (ATTR CA) has gained recognition as a significant cause of heart failure (HF), with affected patients facing a poor prognosis, particularly in advanced stages of the disease [1]. This evidence concerns the gene TTR and hydrops fetalis.